Macular Corneal Dystrophy Type 1Symptoms, Doctors, Treatments, Advances & More
Learn About Macular Corneal Dystrophy Type 1
The Johns Hopkins Hospital
John D. Gottsch, M.D., is the Margaret C. Mosher Professor of Ophthalmology at the Wilmer Eye Institute. Dr. Gottsch specializes in the management of hereditary corneal disorders such as Fuchs' dystrophy, the surgical treatment of cataract and complications of cataract surgery, and corneal transplantation surgery. His clinical practice involves the medical treatment of allergic eye diseases and severe corneal inflammation from rheumatoid and other related disorders, including Mooren''s ulcer. His research interests include determining the gene expression of the cornea and the genetic basis for hereditary corneal diseases such as Fuchs' dystrophy. Dr. Gottsch is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, Corneal Dystrophy and Perceptive Deafness, Cataract, and Corneal Transplant. Dr. Gottsch is board certified in American Board Of Ophthalmology.
The Johns Hopkins Hospital
Allen O. Eghrari, M.D., M.P.H., is director of the Dana Center for Preventive Ophthalmology at the Wilmer Eye Institute and associate professor of ophthalmology at the Johns Hopkins University School of Medicine. He specializes in cornea, cataract and external eye diseases at the Wilmer Eye Institute's locations in Baltimore and Belcamp, Maryland. Dr. Eghrari treats a wide range of eye conditions, with special interest in Fuchs' dystrophy, cataract surgery, cornea transplantation including Descemet Membrane Endothelial Keratoplasty, and Ebola-associated eye disease. Dr. Eghrari received his M.D. degree from the Johns Hopkins University School of Medicine and M.P.H. from the Johns Hopkins Bloomberg School of Public Health. He completed both residency training in ophthalmology and subspecialty fellowship in cornea and cataract surgery at the Wilmer Eye Institute. Dr. Eghrari is a recipient of the Claes Dohlman Society Fellowship Award, the ARVO/Alcon Early Career Clinician-Scientist Award, and the Research to Prevent Blindness Special Scholar Award. Dr. Eghrari is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Cataract, Corneal Transplant, and Cataract Removal. Dr. Eghrari is board certified in American Board Of Ophthalmology.
Price Vision Group
Francis Price is an Ophthalmologist practicing medicine in Indianapolis, Indiana. Dr. Price is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Cataract, Corneal Transplant, and Cataract Removal.
Summary: The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Summary: This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.